Across TCGA pan-cancer cohorts, UBTFL2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of UBTFL2’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where UBTFL2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types UBTFL2 is over-expressed in tumor.
BRCA and LUSC are the cancer types where UBTFL2 tumor–normal differential expression is most reproducible.